The role of vascular endothelial growth factor in ossification

Yan-Qi Yang¹, Ying-Ying Tan¹,², Ricky Wong¹, Alex Wenden¹, Lin-Kun Zhang¹,³ and A Bakr M Rabie⁴

Osteogenesis and angiogenesis are two closely correlated processes during bone growth, development, remodelling and repair. Vascular endothelial growth factor (VEGF) is an essential mediator during the process of angiogenesis. Based on an extensive literature search, which was carried out using the PubMed database and the keywords of osteogenesis, VEGF, endochondral ossification and intramembranous ossification, this manuscript reviews the role of VEGF in ossification, with emphasis on its effect in endochondral and intramembranous ossification. Osteogenesis and angiogenesis are closely correlated processes. VEGF acts as an essential mediator during these processes. It not only functions in bone angiogenesis but also in various aspects of bone development.

International Journal of Oral Science (2012) 4, 64–68; doi:10.1038/ijos.2012.33; published online 22 June 2012

Keywords: endochondral ossification; intramembranous ossification; osteogenesis; vascular endothelial growth factor

INTRODUCTION

Bone formation can occur through two distinct pathways, namely, endochondral ossification and intramembranous ossification.¹⁻² During development of some skull and facial bones or during bone repair, if bone segments are stabilized, mesenchymal precursor cells differentiate directly into bone-forming osteoblasts in a process called intramembranous ossification. This process of ossification occurs in many locations of the skeleton and includes formation of flat bones of the cranium, facial bones and addition to shafts of many other bones. During this process, osteoblasts lay down bone matrix forming spicules. Initially, these spicules lay down trabecular bone, which is eventually replaced with lamellar.¹ Alternatively, during development of long bones and vertebrae or bone repair in a biomechanically unstable environment, bone formation occurs via a cartilage intermediate in a process called endochondral ossification.³ During endochondral ossification, mesenchymal cells differentiate to chondrocytes. Vascular invasion and chondrocytes proliferate in a coordinated process that lengthens the bone.²

Osteogenesis and angiogenesis are two closely correlated processes during bone growth, development, remodelling and repair.¹ Vascular endothelial growth factor (VEGF) is an essential mediator during the process of angiogenesis. Disruption of a single VEGF allele causes embryonic lethality because of defective vasculogenesis, angiogenesis and large vessel formation.⁵⁻⁶ Postnatal ablation of VEGF leads to abnormal organs development because of the reduced vascularisation and angiogenesis.⁷ Except these effects on angiogenesis, VEGF works in both processes of endochondral ossification and intramembranous ossification⁸⁻¹² and acts as an essential mediator during these processes. It is involved not only in bone angiogenesis, but also in various aspects of bone development, including chondrocyte differentiation, osteoblast differentiation and osteoclast recruitment. This article focuses predominately on the role of VEGF in the above two ossification processes.

MATERIALS AND METHODS

A literature search was carried out using PubMed and the keywords—osteogenesis; VEGF; endochondral ossification; and intramembranous ossification. Articles that only described the effect of VEGF on angiogenesis were excluded. A total of 44 references were finally included in this manuscript.

VEGF AND ITS RECEPTORS

VEGF is a specific mitogen for vascular endothelial cells. It was first identified as an endothelial-specific growth factor from bovine pituitary follicular cells by Ferrara and Davis Symth.¹³ The VEGF family consists of seven members, namely, placenta growth factor, VEGF-A, -B, -C, -D, -E and -F.¹³⁻¹⁴ They all share a common structure of eight characteristically spaced cysteine residues in a VEGF homology domain. VEGF-A is the most abundant form and is therefore commonly used in studies investigating the biological effects of VEGF.¹⁵ Thus, VEGF is commonly referred to as VEGF-A.¹⁶ Using this convention, the term VEGF mentioned in this review refers to VEGF-A.

In the osteogenesis–angiogenesis coupling, hypoxia-inducible factor is one of the key upstream regulators of VEGF. Upregulation of hypoxia-inducible factor can be induced not only by the decrease of oxygen tension,¹⁷⁻¹⁸ but also by other stimulus, such as insulin-like growth factor-1.¹⁹⁻²⁰ Recent study indicated that changes of the level of hypoxia-inducible factor can alter the level of VEGF significantly and change the bone mass dramatically.²¹ The biological effects of VEGF are mediated by specific tyrosine kinase receptors (VEGFRs), i.e., Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1) and Vascular endothelial growth factor receptor-2 (VEGFR-2/KDR). Both Flt-1 and KDR can be phosphorylated on tyrosine residues, but show different patterns of potential intracellular substrates in the in vitro immune complex kinase assay and they also mediate different cellular responses. KDR, rather than Flt-1, was found to be the major mediator of essential functions such as

¹Department of Orthodontics, Faculty of Dentistry, The University of Hong Kong, Hong Kong, China; ²Unit Pakar Orthodontik, Klinik Pergigian, Poliklinik Komuniti Mak Mandin, Malaysia; ³Department of Orthodontics, Tianjin Stomatological Hospital of Nankai University, Tianjin, China and ⁴Private Practice

E-mail: yangyan@hku.hk

Received 20 February 2012; accepted 26 April 2012
EFFECTS OF VEGF ON BONE CELLS

Bone is a dynamic tissue in which bone resorption and formation (bone remodelling) occur in a regulated manner under the influence of systemic hormones and local factors. Osteoclasts, the multinucleated giant cells that resorb bone, develop from haematopoietic cells of the monocyte/macrophage lineage. The osteoblast is a type of mononucleate cell, arising from osteoprogenitor cells located in the periosteum and the bone marrow that is responsible for bone formation. Besides producing osteoid, which is composed mainly of type I collagen, osteoblasts are also responsible for mineralisation of the osteoid matrix. Furthermore, osteoblasts and bone marrow stromal cells support osteoclast development via the mechanism of cell-to-cell interaction with osteoclast progenitors.

EFFECTS OF VEGF ON OSTEOBLASTS

VEGF has been implicated in various aspects of osteoblast function. Two studies have shown a dose-dependent chemoattractive effect of VEGF on primary human osteoblasts and human mesenchymal progenitor cells. In addition to its effect on cell migration, VEGF stimulates cell proliferation by up to 70%. It was found that VEGF directly promotes differentiation of primary human osteoblasts in vitro by increasing nodule formation and alkaline phosphatase activity in a dose-dependent manner. Also reported is that VEGF was expressed at low levels at the beginning of osteoblast differentiation and that its expression was strongly increased only during terminal differentiation and reached maximum expression during the period of mineralisation. Thus, VEGF plays an essential role in the regulation of bone remodelling by stimulating osteoblast differentiation.

Mayr-Wohlfart et al. also revealed increased expression of Flt-1 and KDR on human osteoblasts. An in vitro kinase assay failed to demonstrate activation of KDR upon stimulation with VEGF, which is consistent with the idea that the effect of VEGF on primary human osteoblasts is mediated via Flt-1.

EFFECTS OF VEGF ON OSTEOCLASTS

Recent discovery of receptor activator nuclear factor kappa β ligand (RANKL)–RANK interaction confirms the hypothesis that there is a direct contact between osteoblasts and osteoclasts and osteoblasts play an essential role in osteoclast differentiation. Osteoblasts express RANKL as a membrane-associated factor. Osteoclast precursors that express RANK, a receptor for RANKL, recognize RANKL through the cell–cell interaction and differentiate into osteoclasts. Yasuda et al. also identified another key factor for osteoclastogenesis, osteoprotegerin. Osteoprotegerin is produced by osteoblasts or stromal cells and binds to RANKL as a decoy receptor, therefore preventing interaction between RANKL with RANK. Thus, osteoclast differentiation is inhibited by osteoprotegerin.

Min et al. have shown that VEGF can significantly increase both the expression of RANK mRNA and surface protein in human microvascular endothelial cell lines. In addition, they revealed that VEGF mainly enhances RANK expression in endothelial cells through Flk-1/KDR–protein kinase C–ERK signaling pathway, suggesting that VEGF plays an important role in modulating the angiogenic action of RANKL under physiological or pathological conditions. Yao et al. also found that the combination of VEGF and a low dose of colony-stimulating factor-1 can upregulate the RANK expression in osteoclast precursors that is needed for osteoclastogenesis. Nakagawa et al. suggested that VEGF is involved in osteoclastic recruitment, differentiation and enhancement of osteoclastic bone-resorbing activity in cultured rabbit mature osteoclasts.

EFFECTS OF VEGF ON ENDOCHONDRAL OSSIFICATION

Endochondral ossification (also referred to as intracartilaginous ossification) plays a major role in bone formation. It is an essential process during mandibular condylar growth, rudimentary formation and growth of long bones, and the healing of bone fractures. Unlike intramembranous ossification, cartilage, an avascular tissue is present and replaced by bone during endochondral ossification.

Endochondral ossification occurs as chondrocytes undergo proliferation, hypertrophy, cell death and osteoblastic replacement. VEGF has been indicated to serve as an important mediator during the process due to its ability to regulate blood vessel invasion (neovascularisation) into hypertrophic cartilage. The invading blood vessels bring undifferentiated mesenchymal cells into the mineralisation front and later differentiate into osteoblasts and engage in osteogenesis. Also, a recent study by Bluteau et al. for the first time showed that chondrocytes can secrete four members of the VEGF family. VEGF-A, -B, -C and-D were detected and upregulated at the mRNA and protein levels during chondrogenic differentiation of primary chondrocytes in the ATDC5 chondrogenic cell line. This suggests that these factors play an essential role during chondrogenesis. Zelzer et al. provided further in vivo evidence for the important role of VEGF in the process of chondrogenesis.
role of VEGF in blood vessel invasion into hypertrophic cartilage during bone development. More importantly, they described for the first time a connection between VEGF and chondrocyte survival during skeletal development.

During mandibular growth, the condyle undergoes endochondral ossification and the condylar cartilage serves as a template for bone formation. Condylar growth involves a multistage process of cell differentiation, defined by molecules that are synthesized by cells in the condyle. VEGF is expressed at high levels in hypertrophic chondrocytes in the mandibular condyle of growing and adult rats. Maximum levels of VEGF expression precede the maximum level of new bone formation in the condyle. This indicates a close correlation between vascularisation and bone formation. Gene therapy explored in the condylar area by Rabie and co-workers, has shown that recombinant adeno-associated virus-mediated VEGF is an efficient delivery system to induce mandibular condylar growth. Here we see a direct cause and effect. This exogenous VEGF leads to significant condylar growth.

Data from Cortina-Ramírez and Chimal-Monroy suggest differential effects of VEGF on different joints during development. They evaluated VEGF effects on joints by implanting VEGF beads in the presumptive limb joints of chick embryos. The wrist and elbow showed partial and complete fusions. They found that VEGF inhibited joint formation when it was applied after transforming growth factor-beta.

The sphenoid-occipital synchondrosis is an important growth center of the craniofacial skeleton. It forms an important link between the cranial vault and facial skeleton and can influence the positions of the maxilla and mandible. It undergoes endochondral ossification and contributes largely to the expansion of the ossification centres and growth of the cranial base during the postnatal period. Lei et al. identified factors that regulate endochondral ossification in the spheno-occipital synchondrosis through their experiment on mice, in which they found that mechanical stress applied to the spheno-occipital synchondrosis elicits core-binding factor subunit alpha-1 expression and subsequently upregulates the expression of VEGF. Both factors play an important role in growth of the spheno-occipital synchondrosis.

As hypertrophic chondrocytes are avascular, these cells are a potential source of VEGF within the growth plate. To determine the role of VEGF in endochondral bone formation, Gerber et al. inactivated VEGF through the systemic administration of a soluble receptor chimeric protein (Flt-(1–3)-IgG) to 24-day-old mice. Blood vessel invasion was almost completely suppressed, concomitant with impaired terminal chondrocytes decreased. Although proliferation, differentiation and maturation of chondrocytes were apparently normal, resorption was inhibited. Cessation of the anti-VEGF treatment was followed by capillary invasion, restoration of bone growth, resorption of the hypertrophic cartilage and normalisation of the growth plate architecture. These findings indicate that VEGF-mediated capillary invasion is an essential signal that regulates growth plate morphogenesis and triggers cartilage remodelling. Thus, VEGF is a potential coordinator of chondrocyte death, chondroclast function, extracellular matrix remodelling, angiogenesis and bone formation in the growth plate. More investigations are needed to prove this hypothesis.

Healing of fractures is dependent on vascularisation of bone, which is in turn promoted by VEGF. In skeletogenesis, which is tightly linked to angiogenesis, VEGF promotes the vascularisation of the growth plate and transformation of cartilage to bone. Street et al. determined whether VEGF is required for bone repair by inhibiting VEGF activity during secondary bone healing via a cartilage intermediate/endochondral ossification in a novel mouse model. Femoral fractures were used as models of endochondral ossification. Fracture repair occurred in a series of events, involving an initial inflammatory phase, a soft callus phase, a hard callus phase and a remodelling phase. VEGF inhibition in mice by Flt-IgG, a soluble VEGF receptor blocker, disrupted repair of femoral fractures and impaired new bone formation. Their results provide evidence that VEGF activity is essential for conversion of soft cartilaginous callus to a hard bony callus and mineralisation in response to bone injury. Geiger et al. based on their experiment on rabbits, showed that VEGF-gene-activated matrix, led to a significant increase in vascularisation and bone regeneration in large segmental defects. Thus, VEGF-gene-activated matrix can serve as an appropriate tool to promote angiogenesis, osteogenesis and bone healing. Li et al. demonstrated enhanced healing of a segmental defect in the long bone of rabbits using the cell-based VEGF gene transfer without viral vectors. Their findings proved that this delivery method can be effective in management of clinical situations where vascularity is compromised and neovascularisation is to be encouraged, such as fractures with bone loss without the complications regarding viral vectors.

Peng et al. showed interaction between angiogenic and osteogenic factors in bone formation and bone healing. They discovered that the combination of VEGF and bone morphogenetic protein 4 is able to recruit more mesenchymal stem cells to enhance cell survival and to induce cartilage formation in the early stages of endochondral bone formation. Further, the beneficial effect of VEGF on bone healing was found to be dependent on the ratio of VEGF to bone morphogenetic protein 4. Table 1 summarizes the effects of VEGF on endochondral ossification.

**EFFECTS OF VEGF ON INTRAMEMBRANOUS OSSIFICATION**

Intramembranous ossification is a process whereby the formation of bone tissue occurs directly from connective tissue without a preliminary cartilage stage. A good example occurs in the glenoid fossa which is formed when mesenchymal cells directly differentiate into osteoblasts before ultimately forming bone. Experimental studies on rats have shown that mechanical strain caused by forward mandibular positioning stimulates the bone cells in the subperiosteal connective tissue of the glenoid fossa to secrete VEGF. During natural growth and forward mandibular positioning, VEGF expression and new bone formation were the highest in the posterior region of the glenoid fossa. The identification of the temporal sequence of the cellular response revealed that the mesenchymal cells in the posterior region of the glenoid fossa were oriented in the direction of the pull. VEGF enhances neovascularisation, which in turn increases the number of mesenchymal cells in the perivascular connective tissue (Figure 1). VEGF also stimulates the vascular endothelial cells to secrete growth factors and cytokines that influence the differentiation of mesenchymal cells to enter the osteogenic pathway and engage in osteogenesis (Figure 1). Furthermore, the greatest amount of VEGF expression precedes the greatest increase in new bone formation. Therefore, it has been concluded that an increase of VEGF is spatially and temporally related to the amount of new bone formation in the posterior glenoid fossa.

Bone repair is a multistep process which involves migration, proliferation, differentiation and activation of several cells types. Study from Tatsuyama et al. on fracture repair in bone indicates that this
process is complex, occurring through several steps and involving various growth factors including VEGF. Bone growth and bone repair are somehow regulated in a similar manner and thus, VEGF should have a similar effect during bone repair.8 Repair of large bony defects in the craniofacial region represent a major challenge for the surgeon, since autogenous graft material from patients may not be available in sufficient amounts. It has been shown that addition of VEGF to demineralized intramembranous bone matrix (DBMIM) improves the quality and quantity of newly formed bone in the grafted site, thus indicating that VEGF+DBMIM is a good graft material. It is both easily obtainable and could eliminate the need to harvest bone from the patient. Its future application, however, will require further clinical evidence.

Results from Street et al. on mice also show the role of VEGF in intramembranous ossification.27 They have shown direct bone repair through intramembranous ossification in a novel mouse model (tibial cortical bone defects). Inhibition of VEGF by Flt-1-IgG treatment, just as in the femoral fracture model, had distinct effects on bone healing of cortical bone defects. The persistence of unresorbed, unmineralized fracture haematoma at 7 days and the persistence of woven bone at 14 days indicate remodelling defects in Flt-IgG-treated mice. They found that the effects of Flt-IgG on intramembranous bone formation (cortical defects were more prominent at the earlier (7 days) than later (14 days) time point) were due to the fact that intramembranous ossification does not involve a cartilage intermediate. Thus, they suggested that a slow release formulation of VEGF, applied locally at the site of bone damage, can be an effective therapy to promote human bone repair.

Another example of the role of VEGF in intramembranous ossification is observed in distraction osteogenesis, a surgical therapy used in the treatment of skeletal injuries and deformities and in the correction of limb length abnormalities.50 Bone formation during distraction osteogenesis occurs primarily through an intramembranous process. Investigators observed close correlation between optimal angiogenic response and the rate of distraction and speculated that it is this characteristic that drives bone formation through the intramembranous pathway.51 To elucidate the functional role of VEGF signaling during bone formation in distraction osteogenesis, Jacobsen et al. used two blocking antibodies MF-1 (anti-Flt-1) and DC101 (anti-KDR) to specifically disrupt the activities of KDR and Flt-1.52 The results showed that both KDR and Flt-1 play important roles in neovascularisation and bone formation during distraction osteogenesis. Table 2 summarizes the effects of VEGF on intramembranous ossification.

### Table 1 Effects of VEGF on endochondral ossification

| Methods | Materials | Effects | References |
|---------|-----------|---------|------------|
| In vivo | Mouse femur | Stimulated capillary invasion and bone growth | 44 |
| Rat mandibular condyle | Blood vessel invasion (neovascularisation) into hypertrophic cartilage was regulated | 34 |
| Rat mandibular condyle | | 35 |
| Mouse calvarial defects | Synergistic effect between VEGF and BMP4 occurred and recruited more mesenchymal stem cells to enhance cell survival and to induce cartilage formation | 46 |
| Mouse femur fractures healing model | Conversion of soft cartilaginous callus to a hard bony callus and mineralisation was induced | 27 |
| Mouse embryos | VEGF increased blood vessel invasion into hypertrophic cartilage during bone development | 38 |
| Rabbit bone defects | VEGF-GAM (gene-activated matrix) increased vascularity and bone regeneration | 45 |
| Rat mandibular condyle | Mandibular condyle increased in size | 11 |
| Limb joints of chick embryos | Differential effects on different joints: partial fusion on wrist joint; complete fusion on elbow joint; inhibited joint formation when applied after TGF-β | 41 |
| Cranial base synchondroses of mice | Cbfa1 and VEGF promoted growth of the sphenoid-occipital synchondrosis | 43 |
| Rabbit tibial fracture defects | Healing of segmental defect in the long bone of rabbits were enhanced | 12 |
| In vitro | ATDC5 chondrogenic cell line | Stimulated chondrogenic differentiation of primary chondrocytes | 37 |

### Table 2 Effects of VEGF on intramembranous ossification

| Methods | Materials | Effects | References |
|---------|-----------|---------|------------|
| In vivo | Rat tibial fracture defects | VEGF enhanced fracture bone repair | 49 |
| Tibial cortical bone defects | Improved direct bone repair | 27 |
| Rat glenoid fossa | Maximum level of VEGF expression and new bone formation in the posterior region of the glenoid fossa during natural growth and forward mandibular positioning. Greatest amount of VEGF expression precedes the greatest increase in new bone formation | 36 |
| Rat glenoid fossa | Secretion of growth factors and cytokines by vascular endothelial cells was enhanced | 48 |
| Rabbit parietal bone defects | Combination of VEGF and DBMIM is a good graft material | 8 |
| Mouse tibia distraction osteogenesis | Both KDR and Flt-1 play important roles in neovascularisation and bone formation during distraction osteogenesis | 52 |
| In vitro | Distraction osteogenesis | Optimal angiogenic response and rate of distraction are closely related | 51 |

DBMIM, demineralized intramembranous bone matrix; Flt-1, vascular endothelial growth factor receptor-1; KDR, vascular endothelial growth factor receptor-2; VEGF, vascular endothelial growth factor.
CONCLUSION
The evidence from a large amount of research has shown conclusively that VEGF is able to promote ossification by either inducing neo-vascularisation or by directly affecting bone cells. VEGF can stimulate ossification through the two pathways of endochondral ossification and intramembranous ossification.

1 Marks SC, Hermey DC. The structure and development of bone. In: Bilezekian JP, Raizis LD, Rodan GA, editors. Principles of bone biology. San Diego: Academic Press; 1996; 3-24.

2 Kanczler JM, Oreffo RO. Osteogenesis and angiogenesis: the potential for engineering bone. Eur Cell Mater 2008; 2(15): 100–114.

3 Mamandanch VJ, Nelson SC, Bap EA. Current concepts of bone healing. Clin Podiatr Med Surg 2003; 18(1): 55–77.

4 Rabie AB. Vascular endothelial growth pattern during demineralized bone matrix induced osteogenesis. Connect Tissue Res 1997; 36(4): 337–345.

5 Carmellet P, Ferreira V, Breier G et al. Abnormal blood vessel development and infertility in embryos lacking a single VEGF allele. Nature 1996; 380(6573): 435–439.

6 Ferrara N, Carver-Moore K, Chen H. Vascular endothelial growth factor: basic science and clinical progress. In: Bilezekian JP, Rodan GA, editors. Principles of bone biology. San Diego: Academic Press; 1996; 3-24.

7 Gerber HP, Hillan KJ, Ryan AM. VEGF is required for growth and survival in neonatal mice. Development 1999; 126(6): 1149–1159.

8 Emad B, Shifer EF, Basma GM. Vascular endothelial growth factor augments the healing of demineralized bone matrix grafts. Int J Surg 2006; 4(3): 160–166.

9 Dai J, Rabie AB. Direct AAV-mediated gene delivery to the temporomandibular joint. Front Biosci 2007; 12: 2212–2220.

10 Dai J, Rabie AB. Recombinant aden-associated virus vector hybrids efficiently target different skeletal cells. Front Biosci 2007; 12: 4280–4287.

11 Rabie AB, Dai J, Xu R. Recombinant AAV-mediated VEGF gene therapy induces mandibular condylar growth. Gene Ther 2007; 14(12): 972–980.

12 Roy H, Bhardaw J, Yli-Herttuala S. Biology of vascular endothelial growth factors. FEBS Lett 2006; 580(12): 2879–2887.

13 Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem 1996; 271(2): 603–606.

14 Ferrara N, Gerber, HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9(6): 669–676.

15 Poussyse Jany D, Dafan Y, Mazure NM. Hypoxia signaling in cancer and approaches to enforce tumour regression. Nature 2006; 441(7092): 433–434.

16 Chan D, Suthiphan P, Denko N et al. Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha. J Biol Chem 2002; 277(42): 40112–40117.

17 Fukuda R, Horioka K, Fan F. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002; 277(41): 38205–38211.

18 Lee JY, Taghavi T, Chiles K et al. HER2 (neu) signaling increases the rate of hypoxiainducible factor 1alpha (HIF-1alpha)-mediated angiogenic responses in chondrocytes. Biochem Pharmacol 2004; 67(12): 1995–2003.

19 Yang Y, Wan C, Deng L et al. The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest 2007; 117(6): 1616–1626.

20 Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25(4): 581–611.

21 Waltenberger J, Claesson-Welsh L, Siegbahn A et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994; 269(43): 26988–26995.

22 Soker S, Takashima S, Hao H et al. Neuritin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998; 92(6): 735–745.

23 May-Wolfarth F, Waltenberger J, Haussler H et al. Vascular endothelial growth factor stimulates chemotactic migration of primary human osteoblasts. Bone 2002; 30(3): 472–477.

24 Fiedler J, Leucht F, Waltenberger J et al. VEGF-A and PIGF-1 stimulate chemotactic migration of human mesenchymal progenitor cells. Biochim Biophys Acta 2005; 1734(2): 561–568.